[go: up one dir, main page]

MX2018015224A - Composicion que comprende la proteina de fusion de rv2299c y esat-6 para promover la maduracion de las celulas dendriticas. - Google Patents

Composicion que comprende la proteina de fusion de rv2299c y esat-6 para promover la maduracion de las celulas dendriticas.

Info

Publication number
MX2018015224A
MX2018015224A MX2018015224A MX2018015224A MX2018015224A MX 2018015224 A MX2018015224 A MX 2018015224A MX 2018015224 A MX2018015224 A MX 2018015224A MX 2018015224 A MX2018015224 A MX 2018015224A MX 2018015224 A MX2018015224 A MX 2018015224A
Authority
MX
Mexico
Prior art keywords
composition
dendritic cell
rv2299c
esat
fusion protein
Prior art date
Application number
MX2018015224A
Other languages
English (en)
Other versions
MX391634B (es
Inventor
Jung KIM Hwa-
Gyu CHOI Han-
Jae Shin Sung
Original Assignee
Quratis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quratis Inc filed Critical Quratis Inc
Publication of MX2018015224A publication Critical patent/MX2018015224A/es
Publication of MX391634B publication Critical patent/MX391634B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/428Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45Bacterial antigens
    • A61K40/4524Mycobacterium, e.g. Mycobacterium tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una composición para inducir la maduración de células dendríticas y a un método para madurar células dendríticas. Más particularmente, la presente invención se refiere a una composición que incluye una proteína de fusión Rv2299c y ESAT-6, ambas derivadas de M. tuberculosis, como un ingrediente activo para inducir la maduración de células dendríticas y un método para diferenciar células dendríticas inmaduras en células dendríticas maduras utilizando el mismo. El método de la presente invención puede incrementar una respuesta inmune de células dendríticas en el cuerpo.
MX2018015224A 2016-06-07 2017-06-07 Composición que comprende la proteína de fusión de rv2299c y esat-6 para promover la maduración de células dendríticas. MX391634B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160070517A KR101749165B1 (ko) 2016-06-07 2016-06-07 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
PCT/KR2017/005892 WO2017213407A1 (ko) 2016-06-07 2017-06-07 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물

Publications (2)

Publication Number Publication Date
MX2018015224A true MX2018015224A (es) 2019-03-28
MX391634B MX391634B (es) 2025-03-21

Family

ID=59283477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015224A MX391634B (es) 2016-06-07 2017-06-07 Composición que comprende la proteína de fusión de rv2299c y esat-6 para promover la maduración de células dendríticas.

Country Status (11)

Country Link
US (1) US11414646B2 (es)
EP (1) EP3467102B1 (es)
JP (1) JP6683892B2 (es)
KR (1) KR101749165B1 (es)
CN (1) CN109415700B (es)
AU (1) AU2017279377B2 (es)
BR (1) BR112018075291A2 (es)
MX (1) MX391634B (es)
PH (1) PH12018502533A1 (es)
RU (1) RU2733886C2 (es)
WO (1) WO2017213407A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102193304B1 (ko) * 2019-10-24 2020-12-22 충남대학교산학협력단 Rv2299c-ESAT6-HspX-RipA 융합단백질의 BCG 백신 booster용 조성물
KR102878370B1 (ko) * 2022-06-17 2025-10-31 주식회사 미코라파 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물
KR20250057173A (ko) 2023-10-18 2025-04-29 주식회사 큐라티스 결핵 예방용 mRNA 백신 조성물
KR20250087737A (ko) * 2023-12-06 2025-06-17 주식회사 미코라파 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057120A1 (en) * 2002-12-06 2006-03-16 Northwest Biotherapeutics Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
US8273357B2 (en) * 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
CN102149822A (zh) 2008-09-12 2011-08-10 株式会社Lg生命科学 用于检测结核分枝杆菌复合群或分枝杆菌属的组合物和使用所述组合物通过多重实时pcr来同时检测结核分枝杆菌复合群和分枝杆菌属的方法
KR101158649B1 (ko) 2010-05-27 2012-06-26 울산대학교 산학협력단 이중 실시간 중합효소연쇄반응법을 이용한 결핵균과 항산성비결핵균의 검출 방법
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
JP5906019B2 (ja) 2011-03-31 2016-04-20 国立大学法人福井大学 免疫刺激g9.1の抗結核ブースターワクチン創出への応用
KR101264821B1 (ko) * 2011-07-25 2013-05-15 충남대학교산학협력단 결핵균의 Rv0577 단백질을 이용한 수지상 세포의 성숙방법
KR101270999B1 (ko) * 2011-10-11 2013-06-04 충남대학교산학협력단 결핵균의 Rv2299c 단백질을 이용한 수지상 세포의 성숙방법
KR101403507B1 (ko) 2013-03-21 2014-06-09 주식회사 현일바이오 결핵균 및 비결핵 마이코박테리아의 선택적 검출 방법, 그리고 이를 이용한 키트

Also Published As

Publication number Publication date
MX391634B (es) 2025-03-21
BR112018075291A2 (pt) 2019-04-30
CN109415700B (zh) 2022-04-08
AU2017279377B2 (en) 2020-04-30
JP6683892B2 (ja) 2020-04-22
EP3467102A4 (en) 2019-08-28
RU2018141866A3 (es) 2020-07-10
US11414646B2 (en) 2022-08-16
AU2017279377A1 (en) 2018-12-20
EP3467102B1 (en) 2021-09-15
JP2019521183A (ja) 2019-07-25
CN109415700A (zh) 2019-03-01
RU2018141866A (ru) 2020-07-10
US20190153390A1 (en) 2019-05-23
EP3467102A1 (en) 2019-04-10
KR101749165B1 (ko) 2017-06-23
RU2733886C2 (ru) 2020-10-07
WO2017213407A1 (ko) 2017-12-14
PH12018502533A1 (en) 2019-10-21

Similar Documents

Publication Publication Date Title
MX2025001503A (es) Medios y metodo para preparar vectores virales y usos de los mismos
MX2019014960A (es) Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
MX2025009589A (es) Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune
MX2019007020A (es) Anticuerpos il-11.
MY193249A (en) Anti-human cd19 antibodies with high affinity
SG10201803042PA (en) Anti-tim-3 antibodies
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MA39819A (fr) Méthodes et compositions d'immunomodulation
MX379275B (es) Polvo de coleopteros.
PH12018502533A1 (en) COMPOSITION FOR PROMOTING MATURATION OF DENDRITIC CELL CONTAINING FUSION PROTEIN OF Rv2299c AND ESAT-6
WO2013054199A3 (en) Cmv antigens and uses thereof
PH12015502289A1 (en) Creamer composition comprising plant protein microparticles
MY182593A (en) Composition containing chitin and digestible proteins
WO2016126876A3 (en) Listeria-based adjuvants
MY191539A (en) Streptococcal vaccine
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
PH12015501101A1 (en) Method for eliciting an immune response to an immunogen
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2017013855A (es) Metodo para la separacion de proteina y otras impurezas de polisacaridos capsulares microbianos.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MY183068A (en) Pharmaceutical formulation comprising antibody
NZ725212A (en) Group a streptococcus vaccine
MY184391A (en) Microorganism having improved intracellular energy level and method for producing l-amino acid using same
EA201790360A1 (ru) Получение полностью процессированного и функционального фактора x в фурин-секретирующей системе экспрессии млекопитающего